In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...